<DOC>
	<DOCNO>NCT02537158</DOCNO>
	<brief_summary>This study prospective non-randomized control study . The purpose study evaluate validity safety sorafenib transcatheter arterial chemoembolization ( TACE ) microvascular invasion ( MVI ) hepatocellular carcinoma ( HCC ) patient radical surgery .</brief_summary>
	<brief_title>Sorafenib TACE Adjuvant Therapy MVI HCC Patients After Radical Resection</brief_title>
	<detailed_description>HCC sixth common malignancy worldwide.Selected patient HCC candidate potentially curative therapy , hepatic resection liver transplantation . Nevertheless , tumor recurrence 70 % 5 year resection 15-30 % liver transplantation , lead tumor-related death.MVI currently one critical factor predictive HCC recurrence.There approve effective interventional measure improve outcome patient MVI.The purpose study explore validity safety sorafenib TACE MVI HCC patient radical resection.The candidate assign sorafenib group ( 30 case ) , TACE group ( 30 patient ) control group ( 30 case ) ï¼Œaccording willingness subject.All patient follow 3 year Recurrence-free survival overall survival record .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1875 year age ; The liver tumor radically resect ; Postoperative pathology prove hepatocellular carcinoma negative margin microvascular invasion ; Imaging evaluation ( CT/MRI ) perform 1 month resection area enhancement see ; ChildPugh A ; Eastern Cooperative Oncology Group ( ECOG ) body condition score ( PS ) 01 ; Then patient understand voluntarily sign write informed consent ; Recurrent HCC ; pathologyproved multifocal HCC HCC satellite nodule ; Tumor thrombus portal vein inferior vena cava trunk ; Patients extrahepatic metastasis find radiologic pathologic examination ; severe dysfunction heart , kidney , organs.The patient tolerate TACE sorafenib general assessment situation ; Enrolled clinical study time ; Previously treat antitumor treatment except resection ; The researcher believe patient fit study ; Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>sorafenib</keyword>
	<keyword>transcatheter arterial chemoembolization</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>microvascular invasion</keyword>
</DOC>